Abstract
BackgroundOne randomized, controlled clinical field study was conducted in 18 general veterinary practices throughout the USA to evaluate the safety and efficacy of a novel oral chewable combination tablet, Simparica Trio™, containing sarolaner, moxidectin and pyrantel for the treatment and prevention of fleas on dogs.MethodsClient-owned dogs, from households of three or fewer dogs were eligible for enrollment. Four hundred and twenty-two dogs from 251 households were enrolled. Households were randomly assigned in a 2:1 ratio to treatment with either Simparica Trio™ at the minimum label dose of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5 mg/kg pyrantel (as pamoate salt) or afoxolaner (NexGard®, Boehringer-Ingelheim) at the label dose. One dog per household was selected as the primary dog for efficacy evaluations. Treatments were dispensed and dogs were dosed in their home environment on Day 0 and on approximately Day 30. Flea counts and examination for clinical signs of flea allergy dermatitis (FAD) were performed at the initial visit the day before or on Day 0 prior to treatment and on Days 30 and 60. Additionally, all dogs were examined for general health at each visit and blood and urine were collected for clinical pathology at screening and Day 60.ResultsSimparica Trio™ reduced geometric mean live flea counts by 99.0% by Day 30 and by 99.7% by Day 60. As a result of the rapid reduction in flea infestations, clinical signs associated with FAD substantially improved following treatment. Simparica Trio™ was well-tolerated and a diverse range of concomitant medications were administered to dogs during the course of the study. Simparica Trio™ chewable tablets were well-accepted by dogs, with the majority of flavored chewable tablets (91.9%) voluntarily consumed by free choice without, or when offered in food.ConclusionsSimparica Trio™ administered orally once monthly for two consecutive treatments was safe and effective against natural flea infestations and substantially improved clinical signs associated with FAD in client-owned dogs in a field study conducted in the USA.
Highlights
One randomized, controlled clinical field study was conducted in 18 general veterinary practices throughout the United States of America (USA) to evaluate the safety and efficacy of a novel oral chewable combination tablet, Simparica TrioTM, containing sarolaner, moxidectin and pyrantel for the treatment and prevention of fleas on dogs
Simparica TrioTM administered orally once monthly for two consecutive treatments was safe and effective against natural flea infestations and substantially improved clinical signs associated with flea allergy dermatitis (FAD) in client-owned dogs in a field study conducted in the USA
Once a dog is sensitized, recurrence of clinical signs can be initiated by a few bites, the threshold of sensitivity varies between individual dogs [5, 6]
Summary
One randomized, controlled clinical field study was conducted in 18 general veterinary practices throughout the USA to evaluate the safety and efficacy of a novel oral chewable combination tablet, Simparica TrioTM, containing sarolaner, moxidectin and pyrantel for the treatment and prevention of fleas on dogs. Fleas transmit several pathogens, including agents of zoonotic diseases, such as Rickettsia felis [8], Rickettsia typhi [9] and Bartonella henselae [10, 11], and are intermediate hosts for the dog tapeworm [2]. Effective flea control is an important consideration for pet owners and veterinarians given the ubiquitous nature of fleas, blood-feeding habits, and possibility of transmitting diseases to the dog including zoonotic disease agents [13]. To prevent the negative effects and irritation caused by flea feeding and reduce the risks of disease transmission, year-round flea control should be considered for pets in most geographical areas [1, 2]. The effective prevention and control of fleas relies on parasiticides with fast onset of action and consistent efficacy over the dosing interval, as well as pet owner compliance with treatment recommendations
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
